Rockwell Medical (RMTI) Return on Capital Employed (2011 - 2026)
Rockwell Medical (RMTI) posted Return on Capital Employed of 10.15% for Q1 2026, down 3.25% on a QoQ basis from 9.83% in Q4 2025, and down 1141.0% year-over-year from 0.97% in Q1 2025.
Rockwell Medical (RMTI) Return on Capital Employed (2011 - 2026) Analysis & Trends
Rockwell Medical's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 10.15% for Q1 2026.
- Quarterly Return on Capital Employed fell 1141.0% year-over-year to 10.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10.15% (down 1141.0% YoY) and the FY2025 annual result came in at 9.65%, down 1111.0% from the prior year.
- Return on Capital Employed was 10.15% for Q1 2026 at Rockwell Medical, down from 9.83% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1.42% in Q3 2024 and bottomed at 127.21% in Q1 2022.
- A 5-year average of 30.86% and a median of 17.99% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 8304 bps — and 2023, when it soared 8654 bps.
- Rockwell Medical's Return on Capital Employed stood at 51.29% in 2022, then soared by 64 bps to 18.66% in 2023, then jumped by 107 bps to 1.38% in 2024, then plunged by 812 bps to 9.83% in 2025, then retreated by 3 bps to 10.15% in 2026.
- Business Quant data shows RMTI's Return on Capital Employed at 10.15% in Q1 2026, 9.83% in Q4 2025, and 10.58% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Rockwell Medical | 25.77 Mn | 1.88 Mn | 2.90 Mn | -10.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.15% |
| Dec 31, 2025 | -9.83% |
| Sep 30, 2025 | -10.58% |
| Jun 30, 2025 | -3.05% |
| Mar 31, 2025 | 1.26% |
| Dec 31, 2024 | 1.38% |
| Sep 30, 2024 | 1.42% |
| Jun 30, 2024 | -8.36% |
| Mar 31, 2024 | -17.99% |
| Dec 31, 2023 | -18.66% |
| Sep 30, 2023 | -33.83% |
| Jun 30, 2023 | -46.14% |
| Mar 31, 2023 | -40.67% |
| Dec 31, 2022 | -51.29% |
| Sep 30, 2022 | -62.11% |
| Jun 30, 2022 | -88.90% |
| Mar 31, 2022 | -127.21% |
| Dec 31, 2021 | -92.85% |
| Sep 30, 2021 | -76.20% |
| Jun 30, 2021 | -91.51% |